Ensysce CEO Kirkpatrick to Step Down to COO After December 14 Annual Meeting; Director Chang to Resign
ENSC sits 62% above its 52-week low of $0.23 on light trading volume (0.1× avg).
Summary
Ensysce's founder-CEO Lynn Kirkpatrick will become COO immediately after the December 14, 2026 annual meeting as President James Morrisson takes the CEO role, and she has waived severance for the demotion. Director Will Chang also plans to resign after the same meeting.
Key Events · Executive and Board Changes · ENSC
-
CEO Moves to COO Role
Dr. Lynn Kirkpatrick, CEO since January 2009, agreed on October 29, 2026 to take the COO title immediately after the annual meeting, with President James Morrisson becoming CEO.
-
Severance Rights Waived
Amendment No. 1 to her September 14, 2021 employment agreement, executed November 2, 2026, sets the COO start at 5:00 p.m. on January 1, 2027 or earlier upon adjournment of the annual meeting, and includes a Good Reason waiver so the demotion does not trigger severance.
-
Director Chang to Resign
Will Chang advised the board he intends to resign as a director following the annual meeting, scheduled for December 14, 2026; he gave no written resignation or date.
-
Annual Meeting Sets Timing
Both the CEO handover and Chang's departure are tied to the December 14, 2026 annual meeting; a delay in the meeting delays both.
Analysis · ENSC · Life Sciences
Ensysce is handing the CEO role to President James Morrisson right after the December 14, 2026 annual meeting, with founder Lynn Kirkpatrick, CEO since January 2009, moving to COO. The amendment she signed on November 2, 2026 waives her right to claim Good Reason or collect severance over the demotion, so the company avoids a payout and keeps her involved through the transition. Director Will Chang has also said he will leave the board after the same meeting, meaning the board shrinks at the moment leadership changes hands. This lands while shareholders are being asked to approve converting Series C preferred into roughly 358.3 million shares at the December 23, 2026 vote, so a new CEO inherits both a heavily dilutive capital structure and a Nasdaq bid-price deadline extended to February 22, 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENSC was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.23 to $2.17. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.